STRO-002 Continues to Show Promise in Advanced Ovarian Cancer, Early Trial Results Show

STRO-002 Continues to Show Promise in Advanced Ovarian Cancer, Early Trial Results Show
STRO-002, an investigational antibody-drug conjugate, continues to show promising safety and anti-tumor activity in women with advanced ovarian cancer, according to preliminary data from a Phase 1 clinical trial. The findings were presented by Wendel Naumann, MD, principal investigator of the trial, in a recent virtual presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting. Sutro Biopharma’s STRO-002 contains an antibody that specifically binds to folate receptor alpha (FRα), a protein found in high levels in most types of ovarian cancer. This prompts the release of a toxic compound to kill tumor cells, while sparing healthy cells. The safety, tolerability, and preliminary efficacy of STRO-002 are being evaluated in an open-label Phase 1 trial (NCT03748186) in heavily pre-treated women with recurrent platinum-resistant or refractory ovarian cancer (including fallopian and primary peritoneal cancer) and endometrial cancer. Currently recruiting patients in the U.S., the trial intends to enroll about 120 participants. The study is divided into two parts: an initial dose-escalation part, in which women will receive increasing doses of STRO-002 to determine the therapy's optimal dose; and a dose expansion part, in which participants will be treated with the recommended dose. This second phase is planned to start in the second half of this year. While the dose-escalation part of the trial will include only patients with ovarian, fallopian, or primary peritoneal cancer, the dose expansion phase will include an additional group of women with endometrial cancer. Earlier data from this study showed that STRO-002 was generally safe and well-tolerated. One woman receiving the experimental treatment at a dose of 2.9 mg/kg h
Subscribe or to access all post and page content.